Association of Clonal Hematopoiesis With Silent Brain Lesions and Cognitive Decline in Patients With Atrial Fibrillation.
In patients with atrial fibrillation, clonal hematopoiesis is associated with a greater burden of silent brain lesions and accelerated cognitive decline over time.
Where it sits
this study against the rest of the adamax corpusSummary and findings
This study measured the association of clonal hematopoiesis of indeterminate potential (CHIP) with silent brain lesions and cognitive decline in 1572 patients with atrial fibrillation (AF). Participants underwent deep-targeted sequencing, brain MRI, and cognitive assessments over a follow-up period of up to 7 years. The findings indicated that CHIP carriers had higher odds of cerebral microbleeds and white matter lesions, as well as greater cognitive decline compared to non-carriers.
Abstract
Background Clonal hematopoiesis of indeterminate potential (CHIP) has been associated with cardiovascular disease, but its relationship with silent brain lesions and cognitive decline in patients with atrial fibrillation (AF) is unclear. Methods In this prospective, multicenter cohort study, we included 1572 patients with AF enrolled between 2014 and 2017. All participants underwent deep-targeted sequencing for CHIP-associated sequence variations, brain magnetic resonance imaging, and standardized cognitive assessments. CHIP carrier status (overall, DNMT3A carrier, and non-DNMT3A carrier) was evaluated in relation to prevalent and incident silent brain lesions. Silent brain lesions were defined as large noncortical or cortical infarcts, small noncortical infarcts, microbleeds, and white matter lesions (WMLs), and were assessed at baseline and after 2 years with magnetic resonance imaging. Cross-sectional analyses were externally validated in a cohort of 199 patients with AF. Cognitive function was evaluated through 7 years using the Montreal Cognitive Assessment. Associations were analyzed using multivariable-adjusted logistic and linear regression models. Results Among 1572 patients with AF (mean±SD age, 72.5±8.3 years; 26% women), 342 (22%) carried CHIP sequence variations, most commonly in DNMT3A (49.4%) and TET2 (28.3%). CHIP carriers had significantly higher odds of cerebral microbleeds (odds ratio [OR], 1.45 [95% CI, 1.09 to 1.93]) and WMLs (OR, 1.56 [95% CI, 1.20 to 2.04]) at baseline, particularly with non-DNMT3A sequence variations (microbleeds: OR, 1.79 [95% CI, 1.25 to 2.55]; WMLs: OR, 1.80 [95% CI, 1.25 to 2.62]). A similar trend was observed in an independent AF patient cohort from Korea limited to TET2 sequence variations. Presence of multiple CHIP sequence variations further increased the odds of microbleeds (OR, 1.36 [95% CI, 1.10 to 1.69]) and WMLs (OR, 1.41 [95% CI, 1.15 to 1.75]), and large CHIP clones (variant allele frequency >10%) were associated with higher WML volumes. At 2-year follow-up, CHIP was associated with new cerebral microbleed counts and greater WML volume. Over 7 years, CHIP carriers exhibited greater cognitive decline, with a lower Montreal Cognitive Assessment score compared with noncarriers (β -0.53 [95% CI, -1.02 to -0.03]). The decline was more pronounced in DNMT3A and ASXL1 sequence variation carriers. Conclusions In patients with AF, CHIP was independently associated with a greater burden and progression of silent brain lesions and with accelerated cognitive decline. Graphic abstract A graphic abstract is available for this article.
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.